Novo Nordisk faces test as analysts project diverging product sales
Novo Nordisk Reports Nine-Month Figures Amid Portfolio Shifts
Novo Nordisk faces a crucial test on November 4, when the drugmaker releases its nine-month financial figures to show whether rising demand for its newest obesity treatments can offset declining sales across older medications. Analysts expect the Wegovy pill to generate 4.6 billion DKK in third-quarter 2026 revenue, while established injectables experience a pullback.
-
Key Clinical Takeaways:
- Analysts forecast third-quarter 2026 sales for the injectable version of Wegovy to drop by 2.1%.
- Ozempic sales are projected to fall 13.7% down to 26.5 billion DKK, alongside anticipated declines for Rybelsus.
- The broader obesity-treatment portfolio is expected to reach 24.9 billion DKK in revenue, representing an 18.2% increase.
Analyst Consensus Points to Higher Third Quarter Profit Margins
The upcoming accounts arrive as financial markets weigh diverging fortunes across the company product lines rather than a uniform commercial recovery. Consensus estimates point to an adjusted operating profit of 28.4 billion DKK for the third quarter. Gross margins are projected to reach 80.2%, marking an increase from the 76.1% recorded during the third quarter of 2025. Investors are also monitoring how management frames its full-year revenue outlook and whether current demand assumptions remain stable.
Drug List Prices Decline as Upcoming Medical Meetings Approach
Beginning January 1, 2027, US list prices for Wegovy will decrease by approximately 50%, while list prices for Ozempic will fall by around 35%. These scheduled list-price adjustments operate independently of realized selling prices or current revenue effects.
The American Association for the Study of Liver Diseases meeting runs from November 5 to 9, featuring twelve scientific contributions on semaglutide and the investigational drug efruxifermin. A subsequent update follows at ObesityWeek from November 14 to 17, featuring 26 contributions that include low-dose CagriSema results from the REDEFINE 9 trial, real-world utilization data for the Wegovy pill, and findings from the STEP Young study in children. While an exploratory post-hoc analysis of REDEFINE-1 presented approximately two weeks ago associated treatment in women with an average weight loss of 25% after 68 weeks, CagriSema remains an investigational drug that requires independent evaluation of forthcoming trial results.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
